专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210179556A1 PRIMARY CARBOXAMIDES AS BTK INHIBITORS 有权
公开(公告)号：US20210179556A1
公开(公告)日：2021-06-17
申请号：US17173613
申请日：2021-02-11
申请人： AbbVie Inc.
发明人： Dominique Bonafoux , Heather Michele Davis , Kristine E. Frank , Michael M. Friedman , J. Martin Herold , Michael Z. Hoemann , Raymond Huntley , Augustine Osuma , George Sheppard , Gagandeep Kaur Somal , Jennifer Van Camp , Stacy Anne Van Epps , Anil Vasudevan , Grier Allan Wallace , Lu Wang , Lu Wang , Zhi Wang , Noel S. Wilson , Xiangdong Xu
IPC分类号： C07D209/08 , C07D487/04 , C07D417/12 , C07D471/04 , C07D417/14 , C07D401/14 , C07D403/14 , C07D231/56 , C07D401/12 , A61P35/00 , C07D513/04 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/18 , C07D401/04 , C07D403/04 , C07D403/10 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/12 , C07D409/14 , C07D413/04
摘要： The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

2. 发明申请

US20190290645A1 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy 审中-公开
公开(公告)号：US20190290645A1
公开(公告)日：2019-09-26
申请号：US16275938
申请日：2019-02-14
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC分类号： A61K31/501 , A61K31/4433 , A61K31/4192 , A61K31/4178 , C07D405/04 , A61K31/397 , C07D311/58 , C07D405/14 , A61K31/4155
摘要： The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof.The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.

3. 发明授权

US10273238B2 Indazolones as modulators of TNF signaling 有权
公开(公告)号：US10273238B2
公开(公告)日：2019-04-30
申请号：US15852179
申请日：2017-12-22
申请人： AbbVie Inc.
发明人： Eric C. Breinlinger , Andrew Burchat , Justin Dietrich , Michael Friedman , David Ihle , David Kinsman , Kelly Mullen , Augustine Osuma , Anil Vasudevan , Noel S. Wilson
IPC分类号： C07D487/04 , C07D519/00 , C07D498/04
摘要： The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

4. 发明授权

US09586945B2 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy 有权
标题翻译：氨基荧光素，氨基硫辛烷和氨基-1,2,3,4-四氢喹啉衍生物，含有它们的药物组合物及其在治疗中的用途
公开(公告)号：US09586945B2
公开(公告)日：2017-03-07
申请号：US14517034
申请日：2014-10-17
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC分类号： C07D405/04 , C07D405/14 , C07D311/58 , A61K31/352
CPC分类号： A61K31/501 , A61K31/397 , A61K31/4155 , A61K31/4178 , A61K31/4192 , A61K31/4433 , C07D311/58 , C07D405/04 , C07D405/14
摘要： The present invention relates to aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, and the use of such aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives for therapeutic purposes. The aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives are GlyT1 inhibitors.
摘要翻译：本发明涉及包含这种氨基苯并二氢吡喃，氨基硫辛烷和氨基-1,2,3,4-四氢喹啉衍生物的药物组合物，以及用于治疗目的的这种氨基苯并二氢吡喃，氨基硫辛烷和氨基-1,2,3,4-四氢喹啉衍生物的用途。氨基苯并二氢吡喃，氨基硫色烷和氨基-1,2,3,4-四氢喹啉衍生物是GlyT1抑制剂。

5. 发明授权

US09586942B2 Aminotetraline and aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy 有权
标题翻译：氨基四氢化萘和氨基茚满衍生物，含有它们的药物组合物及其在治疗中的应用
公开(公告)号：US09586942B2
公开(公告)日：2017-03-07
申请号：US14517205
申请日：2014-10-17
申请人： AbbVie Deutschland GmbH & Co. KG , AbbVie Inc.
发明人： Wilhelm Amberg , Frauke Pohlki , Udo Lange , Ying Wang , Jason Brewer , Anil Vasudevan , Yanbin Lao , Charles Hutchins , Hongyu Zhao , Huan-Qiu Li
IPC分类号： C07D403/12 , C07D401/12 , C07D233/42 , C07D207/273 , C07D205/04 , C07D403/14 , C07D403/10 , C07D405/14 , A61K31/4164
CPC分类号： A61K31/454 , A61K31/397 , A61K31/4025 , A61K31/4178 , A61K31/4192 , C07D205/04 , C07D207/273 , C07D233/42 , C07D401/12 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/14
摘要： The present invention relates to aminotetraline and aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline and aminoindane derivatives, and the use of such aminotetraline and aminoindane derivatives for therapeutic purposes. The aminotetraline and aminoindane derivatives are GlyT1 inhibitors.
摘要翻译：本发明涉及包含这种氨基四氢化萘和氨基茚满衍生物的药物组合物，以及这种氨基四氢化萘和氨基茚满衍生物用于治疗目的的用途。氨基四氢化萘和氨基茚满衍生物是GlyT1抑制剂。

6. 发明申请

US20160304526A1 INDAZOLONES AS MODULATORS OF TNF SIGNALING 有权
标题翻译：作为TNF信号调节剂的吲哚酮
公开(公告)号：US20160304526A1
公开(公告)日：2016-10-20
申请号：US15130323
申请日：2016-04-15
申请人： AbbVie Inc.
发明人： Eric Breinlinger , Andrew Burchat , Justin Dietrich , Michael Friedman , David Ihle , David Kinsman , Kelly Mullen , Augustine Osuma , Anil Vasudevan , Noel Wilson
IPC分类号： C07D487/04 , C07D498/04 , C07D519/00
CPC分类号： C07D487/04 , C07D498/04 , C07D519/00
摘要： The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.
摘要翻译：药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本公开的化合物可用于治疗免疫学和肿瘤学病症。

7. 发明申请

US20160304517A1 TRICYCLIC MODULATORS OF TNF SIGNALING 有权
标题翻译： TNF信号的TRICYCLIC调节剂
公开(公告)号：US20160304517A1
公开(公告)日：2016-10-20
申请号：US15130362
申请日：2016-04-15
申请人： AbbVie Inc.
发明人： Eric C. Breinlinger , Phil B. Cox , Jerome Daanen , Justin Dietrich , Stevan Djuric , Amanda W. Dombrowski , Kristine E. Frank , Michael M. Friedman , Arthur Gomtsyan , Huan-Qui Li , Kenton Longenecker , Augustine Osuma , Ann Marie Rowley , Robert Schmidt , Anil Vasudevan , Noel Wilson
IPC分类号： C07D471/04 , C07D491/147 , C07D491/22 , C07D498/04 , C07D471/18 , C07D471/14 , C07D498/22 , C07D498/14 , C07D498/20 , C07D487/04 , C07D519/00
CPC分类号： C07D471/04 , C07D471/14 , C07D471/18 , C07D487/04 , C07D491/147 , C07D491/22 , C07D498/04 , C07D498/14 , C07D498/18 , C07D498/20 , C07D498/22 , C07D519/00
摘要： The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.
摘要翻译：本发明提供三环杂环化合物，药学上可接受的盐，前药，生物活性代谢物，立体异构体和异构体，其中变量在本文中定义。本发明的化合物可用于治疗免疫学和肿瘤学病症。

8. 发明申请

US20160068521A1 THIAZOLES AND USES THEREOF 审中-公开
标题翻译： THIAZOLES及其用途
公开(公告)号：US20160068521A1
公开(公告)日：2016-03-10
申请号：US14786454
申请日：2014-04-22
申请人： ABBVIE INC.
发明人： Iok Chan Ng , M-akhteruzzaman Molla , Tami J. Pilot-Matias , Anil Vasudevan , Tatyana Dekhtyar , Artour Gomtsian , Katerina Sarris , Ana Aguirre , Mikhail Chafeev
IPC分类号： C07D417/14 , A61K31/506 , A61K31/501 , A61K31/4178 , A61K31/433 , A61K31/4439 , A61K31/427 , C07D403/14
CPC分类号： C07D417/14 , A61K31/4178 , A61K31/427 , A61K31/433 , A61K31/4439 , A61K31/501 , A61K31/506 , A61K45/06 , C07D403/14
摘要： This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.
摘要翻译：本公开涉及：（a）其特别是抑制RSV感染和/或复制的化合物及其盐; （b）可用于制备这些化合物和盐的中间体; （c）包含这些化合物和盐的组合物; （d）制备这种中间体，化合物，盐和组合物的方法; （e）使用这些化合物，盐和组合物的方法; 和（f）包含这些化合物，盐和组合物的试剂盒。

9. 发明申请

US20150105386A1 4-(4-PYRIDINYL)-BENZAMIDES AND THEIR USE AS ROCK ACTIVITY MODULATORS 审中-公开
标题翻译： 4-（4-吡啶基） - 苯甲酸酯及其作为岩石活性调节剂的用途
公开(公告)号：US20150105386A1
公开(公告)日：2015-04-16
申请号：US14523296
申请日：2014-10-24
申请人： AbbVie Deutschland GmbH & Co KG , AbbVie Inc.
发明人： Helmut Mack , Nicole Teusch , Bernhard K. Muller , Wilfried Hornberger , Michael F. Jarvis , Daryl Sauer , Steven L. Swann, Jr. , Dominique Bonafoux , Ryan Keddy , Adrian Donald Hobson , Anil Vasudevan
IPC分类号： C07D401/12 , C07D213/56
CPC分类号： C07D401/12 , C07D213/56 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs). R1 and R2 are, independently of each other, hydrogen, hydroxy, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy or C1-C8-haloalkoxy; R3, R4, R5 and R6 are, independently of each other, hydrogen, hydroxy, halogen, cyano, C1-C8-alkyl, C1-C8-haloalkyl, C1-C8-alkoxy, C1-C8-haloalkoxy, amino, C1-C8-alkylamino or di-(C1-C8-alkyl)-amino; R7 is hydrogen, C1-C8-alkyl, C1-C8-haloalkyl, aryl or aryl-C1-C8-alkyl; R8 is a group of the formula —X—W, where X is a single bond, C1-C4-alkylene or C1-C4-alkylene-O—, where the alkylene group in the three last-mentioned radicals may be linear or branched and may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or may be interrupted by an oxygen atom; and W is a cyclic radical selected from phenyl and a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring which contains as ring members 1, 2 or 3 heteroatoms selected O, S, and N and optionally 1 or 2 carbonyl groups; R9 is a group of the formula —Y—Z, where Z is hydrogen, halogen, OR11, NR12R13, S(O)m—R14, phenyl which may carry 1, 2, 3 or 4 substituents R15 or a 5- or 6-membered saturated, partly unsaturated or aromatic heterocyclic ring; and Y is linear or branched C1C4-alkylene which may be partly or fully halogenated and/or may be substituted by a hydroxyl group and/or a phenyl ring; or, in case Z is phenyl or the 5- or 6-membered heterocyclic ring as defined above, Y can also be a single bond.
摘要翻译：本发明涉及式（I）的新型4-（4-吡啶基） - 苯甲酰胺。化合物I具有有价值的治疗特性，特别适用于治疗对Rho激酶（ROCK）的调节作用的疾病。 R 1和R 2彼此独立地为氢，羟基，氰基，C 1 -C 8 - 烷基，C 1 -C 8 - 卤代烷基，C 1 -C 8 - 烷氧基或C 1 -C 8 - 卤代烷氧基; R3，R4，R5和R6彼此独立地为氢，羟基，卤素，氰基，C1-C8-烷基，C1-C8-卤代烷基，C1-C8-烷氧基，C1-C8-卤代烷氧基，氨基，C1- C 8 - 烷基氨基或二 - （C 1 -C 8 - 烷基） - 氨基; R 7是氢，C 1 -C 8 - 烷基，C 1 -C 8 - 卤代烷基，芳基或芳基-C 1 -C 8 - 烷基; R8是式-X-W的基团，其中X是单键，C1-C4-亚烷基或C1-C4-亚烷基-O-，其中三个最后提到的基团中的亚烷基可以是直链或支链并且可以部分或完全卤化和/或可以被羟基取代和/或可以被氧原子中断; 并且W是选自苯基和5-或6-元饱和，部分不饱和或芳族杂环的环状基团，其包含作为环成员1,2或3的选自O，S和N的杂原子和任选的1或2个羰基 ; R 9是式-Y-Z的基团，其中Z是氢，卤素，OR 11，NR 12 R 13，S（O）m -R 14，可带有1,2,3或4个取代基R 15或5-或6的苯基饱和的，部分不饱和的或芳族的杂环; Y是可部分或完全卤化和/或可被羟基和/或苯环取代的直链或支链C 1 -C 4亚烷基; 或者Z为苯基或上述5-或6-元杂环的情况下，Y也可以是单键。

10. 发明授权

US10556914B2 Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use 有权
公开(公告)号：US10556914B2
公开(公告)日：2020-02-11
申请号：US16409323
申请日：2019-05-10
申请人： AbbVie Inc. , AbbVie Deutschland GmbH & Co. KG
发明人： Jürgen Dinges , Achim Moeller , Michael Ochse , Martin Schmidt , Michael Schulz , Sean Turner , Elizabeth Louise Van Der Kam , Anil Vasudevan
IPC分类号： C07D498/04 , C07D513/04 , A61K31/4985
摘要： Compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modulation of the γ-aminobutyric acid B (GABA-B) receptor. Methods for making the compounds are described. Also described are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式